DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025

Core Points - Diagnos Inc. intends to extend the exercise period of 1,125,000 stock warrants from November 9, 2025, to August 5, 2026, subject to TSX Venture Exchange consent [1][2] - The exercise price of the warrants will remain unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos is a publicly traded Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [4] - The company's technology aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [4]